Girard Charlotte, Charles Pierre, Terrier Benjamin, Bussonne Guillaume, Cohen Pascal, Pagnoux Christian, Cottin Vincent, Cordier Jean-François, Guillevin Loïc
From the Department of Internal Medicine (CG, PaC, BT, GB, LG), National Referral Center for Rare Autoimmune and Systemic Diseases, Cochin Hospital; INSERM U1060 (CG, PaC, BT, GB, LG), Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, University of Paris 5-René-Descartes, Paris; Department of Internal Medicine (CG), Department of Rheumatology, Mount Sinaï Hospital, Toronto, Ontario, Canada (CP), Edouard-Herriot University Hospital, Lyon; National Referral Center for Rare Pulmonary Diseases (VC, J-FC), Louis-Pradel Hospital, Lyon, France; and Department of Internal Medicine (PiC), Institut Mutualiste Montsouris, Paris.
Medicine (Baltimore). 2015 Aug;94(32):e1088. doi: 10.1097/MD.0000000000001088.
Tracheobronchial stenoses (TBSs) are potentially severe manifestations of granulomatosis with polyangiitis (Wegener's) (GPA) that usually respond poorly to corticosteroids and immunosuppressive agents. We describe 26 GPA patients with ≥1 tracheal (mainly subglottic, SGS) and/or bronchial stenosis(ses) (BS(s)).Sixteen patients had solitary SGS and 10 had ≥1 BS(s). The male/female sex ratio was 9:17, and the median age at GPA diagnosis was 32 years (3:13 and 28 years, respectively, for SGS patients). Antineutrophil cytoplasm antibodies were proteinase 3-positive in 65.5% of the patients (50% of those with SGS).Despite conventional GPA therapy, 62% patients experienced ≥1 stenosis relapse(s) (81% of SGS patients, for a total of 1-8 relapses per patient). None of the several systemic or endoscopic treatments prevented future relapses. Cyclophosphamide induction therapy was effective in 4/6 patients with BS(s) and in 1 patient with SGS among the 7 treated. After many relapses, rituximab achieved remission in 3/4 SGS patients. Endoscopic treatments (dilation, laser, corticosteroid injection, etc.) had only transient efficacy. Other GPA manifestations relapsed independently of TBSs. One SGS patient died of acute respiratory distress syndrome.Our findings confirmed that TBSs are severe GPA manifestations that evolve independently of other organ involvements and do not respond to conventional systemic regimens. As previously described, our population was younger and comprised more females than usual GPA patients, especially those with SGS.The small number of patients and the wide variety of local and systemic treatments prevent us from drawing definitive conclusions about the contribution of each procedure. However, cyclophosphamide seemed to effectively treat BSs, but not SGS, and rituximab may be of interest for SGS management.
气管支气管狭窄(TBS)是肉芽肿性多血管炎(韦格纳肉芽肿,GPA)的潜在严重表现,通常对皮质类固醇和免疫抑制剂反应不佳。我们描述了26例患有≥1处气管(主要是声门下,SGS)和/或支气管狭窄(BS)的GPA患者。16例患者有孤立性SGS,10例有≥1处BS。男女比例为9:17,GPA诊断时的中位年龄为32岁(SGS患者分别为31岁和28岁)。65.5%的患者抗中性粒细胞胞浆抗体为蛋白酶3阳性(SGS患者中为50%)。尽管采用了传统的GPA治疗方法,62%的患者经历了≥1次狭窄复发(SGS患者中为81%,每位患者复发1 - 8次)。几种全身或内镜治疗均未能预防未来的复发。环磷酰胺诱导治疗对7例接受治疗的患者中的4例BS患者和1例SGS患者有效。经过多次复发后,利妥昔单抗使3/4的SGS患者病情缓解。内镜治疗(扩张、激光、皮质类固醇注射等)仅具有短暂疗效。其他GPA表现独立于TBS复发。1例SGS患者死于急性呼吸窘迫综合征。我们的研究结果证实,TBS是严重的GPA表现,其发展独立于其他器官受累情况,且对传统全身治疗方案无反应。如前所述,我们研究中的患者比普通GPA患者更年轻,女性更多,尤其是SGS患者。患者数量较少以及局部和全身治疗方法多样,使我们无法就每种治疗方法的作用得出明确结论。然而,环磷酰胺似乎能有效治疗BS,但不能治疗SGS,利妥昔单抗可能对SGS的治疗有意义。